Glycyrrhizic-acid-Glycyrrhizin-DataSheet-生命科學試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEGlycyrrhizicacidCat.No.:HY-N0184CASNo.:1405-86-3Synonyms:Glycyrrhizin分?式:C??H??O??分?量:822.93作?靶點:VirusProtease作?通路:Anti-infection儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:500mg/mL(607.59mM;Needultrasonic)H2O:<0.1mg/mL(insoluble)MassSolvent1mg5mg10mgConcentration制備儲備液1mM1.2152mL6.0759mL12.1517mL5mM0.2430mL1.2152mL2.4303mL10mM0.1215mL0.6076mL1.2152mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥22.5mg/mL(27.34mM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:10mg/mL(12.15mM);Suspendedsolution;Needultrasonic3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:10mg/mL(12.15mM);Suspendedsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性Glycyrrhizicacid?草?的活性成分三萜皂苷，為HMGB1的拮抗劑，有?于腫瘤、糖尿病等研究的潛?。體外研究Glycyrrhizicacidshowsaseriesofanti-cancer-relatedpharmacologicalactivities,suchasbroad-spectrumanti-cancerability,resistancetothetissuetoxicitycausedbychemotherapyandradiation,drugabsorptionenhancingeffectsandanti-multidrugresistance(MDR)mechanisms,asacarriermaterialindrugdeliverysystems[1].InintestinalNCI-H716cellsthatsecretesGLP-1,GlycyrrhizicacidpromotesGLP-1secretionwithamarkedelevationofcalciumlevels.GlycyrrhizicacidcanenhanceGLP-1secretionthroughTGR5activation[2].Glycyrrhizicacidcanformastabletransparentlow-molecular-weighthydrogels(LMWHs)at37°Cinphysiologicalphosphatebufferedsaline(PBS)withnanoclustersasthemicrostructures[4].體內(nèi)研究Intype1-likediabeticratsinducedbystreptozotocin(STZ-treatedrats),GlycyrrhizicacidincreasesthelevelofplasmaGLP-1,whichisblockedbytriamtereneatadosesufficienttoinhibitTakedaG-protein-coupledreceptor5(TGR5)[1].Glycyrrhizicacid(Glycyrrhizicacid;50mg/kg,i.p.)significantlydecreasesthelevelsofTgAb,HMGB1,TNF-α,IL-6,IL-1βinmice[3].PROTOCOLAnimalMice[3]Administration[3]NOD.H-2h4micearefedintheanimalhouseuntil4weeksofage.Atotalof24malemicearethenrandomlyseparatedintothreedifferentgroups(n=8pergroup).Miceinthecontrolgrouparegivensterilewaterwithoutsupplement.Miceintheiodinesupplement(NaI)grouparegiven0.005%NaIinthedrinkingwater.MiceintheNaI+Glycyrrhizicacidgrouparetreatedwith50mg/kgGlycyrrhizicacidoncedailyfor4weeks,administeredviaintraperitonealinjectionafter8weeksofiodinesupplementation.Thyroidtissuesareremovedsurgicallyunderanesthesia,washedwithcoldsaline,blottedonfilterpaperandweighedusinganelectronicbalance.Thethyroidglandtissuesarethenstoredat-80°Cuntiluse[3].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻?CellProlif.2020Jun;53(6):e12829.?FrontCellDevBiol.2020Aug11;8:713.2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE?ACSChemNeurosci.2020Mar18;11(6):979-993.?Aging(AlbanyNY).2019Jul7;11(13):4323-4337.?JFunctFoods.2021,104584.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].SuX,etal.Glycyrrhizicacid:Apromisingcarriermaterialforanticancertherapy.BiomedPharmacother.2017Sep5;95:670-678[2].WangLY,etal.Glycyrrhizicacidincreasesglucagonlikepeptide-1secretionviaTGR5activationintype1-likediabeticrats.BiomedPharmacother.2017Sep4;95:599-604.[3].LiC,etal.Glycyrrhizin,aDirectHMGB1Antagonist,AmelioratesInflammatoryInfiltrationinaModelofAutoimmuneThyroiditisviaInhibitionofTLR2-HMGB1Signaling.Thyroid.2017May;27(5):722-731.[4].XiaZhao,etal.ASimpleInjectableMoldableHydrogelAssembledfromNaturalGlycyrrhizicAcidwithInherentAntibacterialActivity.ACSAppl.BioMater.2020,3,1,6